Literature DB >> 27908697

Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection.

D G Burke1, M J Harrison2, C Fleming2, M McCarthy2, C Shortt2, I Sulaiman3, D M Murphy2, J A Eustace4, F Shanahan1, C Hill5, C Stanton6, M C Rea6, R P Ross1, B J Plant7.   

Abstract

Clostridium difficile is an anaerobic Gram-positive, spore-forming, toxin-producing bacillus transmitted among humans through the faecal-oral route. Despite increasing carriage rates and the presence of C. difficile toxin in stool, patients with CF rarely appear to develop typical manifestations of C. difficile infection (CDI). In this study, we examined the carriage, toxin production, ribotype distribution and antibiotic susceptibility of C. difficile in a cohort of 60 adult patients with CF who were pre-lung transplant. C. difficile was detected in 50% (30/60) of patients with CF by culturing for the bacteria. C. difficile toxin was detected in 63% (19/30) of C. difficile-positive stool samples. All toxin-positive stool samples contained toxigenic C. difficile strains harbouring toxin genes, tcdA and tcdB. Despite the presence of C. difficile and its toxin in patient stool, no acute gastrointestinal symptoms were reported. Ribotyping of C. difficile strains revealed 16 distinct ribotypes (RT), 11 of which are known to be disease-causing including the hyper-virulent RT078. Additionally, strains RT002, RT014, and RT015, which are common in non-CF nosocomial infection were described. All strains were susceptible to vancomycin, metronidazole, fusidic acid and rifampicin. No correlation was observed between carriage of C. difficile or any characteristics of isolated strains and any recorded clinical parameters or treatment received. We demonstrate a high prevalence of hypervirulent, toxigenic strains of C. difficile in asymptomatic patients with CF. This highlights the potential role of asymptomatic patients with CF in nosocomial transmission of C. difficile.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Cystic fibrosis; Nosocomial infection; Transmission

Mesh:

Year:  2016        PMID: 27908697     DOI: 10.1016/j.jcf.2016.09.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

1.  Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Zev H Davidovics; Sonia Michail; Maribeth R Nicholson; Larry K Kociolek; Nikhil Pai; Richard Hansen; Tobias Schwerd; Aldo Maspons; Raanan Shamir; Hania Szajewska; Nikhil Thapar; Tim de Meij; Alexis Mosca; Yvan Vandenplas; Stacy A Kahn; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-01       Impact factor: 2.839

Review 2.  Luminal Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Samuel J Burton; Christine Hachem; James M Abraham
Journal:  Curr Gastroenterol Rep       Date:  2021-03-23

Review 3.  Clinical Phenotypes of Cystic Fibrosis Carriers.

Authors:  Philip M Polgreen; Alejandro P Comellas
Journal:  Annu Rev Med       Date:  2022-01-27       Impact factor: 13.739

Review 4.  Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.

Authors:  Diego J Maselli; Holly Keyt; Marcos I Restrepo
Journal:  Int J Mol Sci       Date:  2017-05-16       Impact factor: 5.923

5.  The altered gut microbiota in adults with cystic fibrosis.

Authors:  D G Burke; F Fouhy; M J Harrison; M C Rea; P D Cotter; O O'Sullivan; C Stanton; C Hill; F Shanahan; B J Plant; R P Ross
Journal:  BMC Microbiol       Date:  2017-03-09       Impact factor: 3.605

Review 6.  The Gut-Lung Axis in Cystic Fibrosis.

Authors:  Courtney E Price; George A O'Toole
Journal:  J Bacteriol       Date:  2021-08-02       Impact factor: 3.476

7.  High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.

Authors:  Tanya M Monaghan; Ola H Negm; Brendon MacKenzie; Mohamed R Hamed; Clifford C Shone; David P Humphreys; K Ravi Acharya; Mark H Wilcox
Journal:  Clin Exp Gastroenterol       Date:  2017-07-19

8.  Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis.

Authors:  Maiara Brusco de Freitas; Emilia Addison Machado Moreira; Camila Tomio; Yara Maria Franco Moreno; Felipe Perozzo Daltoe; Eliana Barbosa; Norberto Ludwig Neto; Vittoria Buccigrossi; Alfredo Guarino
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

9.  Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut.

Authors:  Yanan Wang; Lex E X Leong; Rebecca L Keating; Tokuwa Kanno; Guy C J Abell; Fredrick M Mobegi; Jocelyn M Choo; Steve L Wesselingh; A James Mason; Lucy D Burr; Geraint B Rogers
Journal:  Gut Microbes       Date:  2018-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.